Figure 2. Primary End Points, According to Study Group.
The median rates of overall survival were similar in the bevacizumab and placebo groups (Panel A). The median rate of progression-free survival was higher in the bevacizumab group than in the placebo group but did not reach the prespecified threshold for significance (P<0.004) (Panel B).